US FDA requests removal of suicide warnings from weight-loss drugs
I'm PortAI, I can summarize articles.
Jan 13 (Reuters) - The U.S. Food and Drug Administration on Tuesday requested companies to remove warnings related to the potential risk of suicidal ideation from the labeling of popular weight-loss drugs of the GLP-1 class.The action follows a comprehensive FDA review that found no increased risk of suicidal ideation and behavior associated with the use of GLP-1 drugs, which include Novo Nordisk’s (NOVOb.CO) Wegovy and older drug Saxenda, and Eli Lilly’sZepbound.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments